Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Objective: To review drug interaction studies of glucagon-like ... needed to further assess and allow comparison of several GLP-1RA agents' impact on steady-state pharmacokinetics and ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

Metsera Announces Positive Topline Phase 2a Clinical Data for its Ultra-Long Acting GLP-1 Receptor Agonist, MET-097i ...

MET-097i was tested in five cohorts of 24 participants (20 active drug, 4 placebo ... ultra-long acting, GLP-1RA. The company plans to launch an additional study to confirm this finding across ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

However, due to their success in helping with weight management, the Food and Drug Administration (FDA ... If a person decides to start GLP-1RA treatment, careful monitoring is essential to ...